Researchers at the Jonsson Comprehensive Cancer Center at UCLA have received a five-year, $5 million grant to conduct artificial intelligence detection research for aggressive prostate cancer. Funded by the National Cancer Institute, the aim is to discover new cancer biomarkers and develop AI technologies for the detection and prediction of aggressive prostate cancer. Despite some progress in the diagnosis and treatment of prostate cancer, the disease remains a widespread issue in men's health.

Cancer detection startup C2i Genomics has partnered with Tel Aviv's Sourasky Medical Center, Israel's top hospital, to utilize cloud-based artificial intelligence solutions for early cancer detection. C2i Genomics focuses on whole-genome minimal residual disease (MRD) detection to enhance cancer detection and monitoring capabilities. The collaboration will advance internal research and clinical trials at the hospital and facilitate drug development for pharmaceutical companies.

{1:C2i Genomics, a cancer detection startup, collaborates with Israel's top hospital, Tel Aviv Sourasky Medical Center, to utilize cloud-based AI solutions for early cancer detection. 2:C2i Genomics focuses on whole genome minimal residual disease (MRD) detection to enhance the ability to detect and monitor cancer. 3:The collaboration will drive internal research and clinical trials at the hospital and promote drug development by pharmaceutical companies.}